Flexible End-To-End Engagement Models and Customized Approaches
In recent years, cell and gene therapy (CGT) has developed rapidly, raising the bar for research, manufacturing and clinical development. Tigermed’s team of experts in cell and gene therapy clinical trials covers a wide range of cell, gene and small nucleic acid products, including gene therapy, stem cells, CAR-T, CAR-NK, TCR-T, TIL and red blood cell therapies, across indications such as multiple myeloma, lymphoma, hemophilia, rare diseases and autoimmune diseases.In terms of industry resources, Tigermed’s cell and gene therapy solutions have a team of top experts, 100+ KOL resources, more than 200 professional CGT strategic cooperation centers, as well as a number of cooperative GCP centers and scientific research institutions, integrating advantageous resources to serve CGT customers.
In addition, relying on the integrated R&D service platform for innovative drugs, Tigermed’s professional CGT solutions can provide integrated and specialized cell and gene therapy CRO services ranging from preclinical super-cell donor library screening services, CMC, pharmacodynamic modeling exploration, pharmacology and toxicology, GLP safety assessment center, registration, medicine, operation, numerical statistics, PV, MM, SMO, CGT special testing project center laboratory, etc., and provide customized services for R&D institutions according to their needs. We can also provide R&D institutions with customized cell and gene therapy consulting, including project strategy planning, and other professional services according to their needs, so as to accelerate the clinical development and marketing process of CGT products in an efficient and high-quality way.
